Bence-Jones Protein λ-type Multiple Myeloma Patient Withdrawn from Maintenance Hemodialysis after Long-term Bortezomib and Dexamethasone Therapy
-
- Yamaguchi Wakaba
- Department of Nephrology, Tokyo Medical and Dental University, Japan
-
- Yui Naofumi
- Department of Nephrology, Tokyo Medical and Dental University, Japan
-
- Nagao Toshikage
- Department of Hematology, Tokyo Medical and Dental University, Japan
-
- Oshikawa Gaku
- Department of Hematology, Tokyo Medical and Dental University, Japan
-
- Negi Mariko
- Department of Pathology, Tokyo Medical and Dental University, Japan
-
- Iimori Soichiro
- Department of Nephrology, Tokyo Medical and Dental University, Japan
-
- Okado Tomokazu
- Department of Nephrology, Tokyo Medical and Dental University, Japan
-
- Rai Tatemitsu
- Department of Nephrology, Tokyo Medical and Dental University, Japan
-
- Uchida Shinichi
- Department of Nephrology, Tokyo Medical and Dental University, Japan
Bibliographic Information
- Other Title
-
- Bence-Jones Protein λ-type Multiple Myeloma Patient Withdrawn from Maintenance Hemodialysis after Long-term Bortezomib and Dexamethasone Therapy
Search this article
Abstract
The effectiveness of bortezomib treatment for multiple myeloma (MM) is well established. However, the protocol by which maintenance therapy using bortezomib should be continued for myeloma patients requiring regular hemodialysis remains to be established. We herein report a case of MM with severe renal insufficiency requiring hemodialysis for nearly 30 months which was finally withdrawn from renal replacement therapy during monthly maintenance treatment with bortezomib and dexamethasone for two years. The details of this case are essential for establishing clinical guidelines for applying intermittent low-frequency bortezomib therapy in dialysis-dependent myeloma patients.<br>
Journal
-
- Internal Medicine
-
Internal Medicine 55 (3), 263-268, 2016
The Japanese Society of Internal Medicine
